The clinical course for primary cutaneous acral CD8+ T-cell lymphoma is invariably indolent; cutaneous relapse may occur, but there have been no reports of progression to extracutaneous sites, and overtreatment should be avoided (238). This evidence concerns the gene CD8A and T-cell non-Hodgkin lymphoma.